History Article
Close
This entry was posted on June 9, 2014 at 20:28.
The last change is the June 9, 2014 at 20:31.
health industry, and the pharmaceutical industry in the first place, as a driver of growth and competitiveness Italian and European but also as a primary asset to ensure the sustainability of health care systems around the world. And as a glue to create a Europe of Health is now dangerously broken. These numbers are excellent and the group photo of a solid industrial background that those “I-Com”, the Institute for Competitiveness, presented in Rome tomorrow in support of its “Report 2014 ‘in view of the upcoming semester Italian Presidency of the EU. Where “Growing up in health in Italy and in Europe,” wants to be a challenge and a point of recovery.
“The pharmaceutical industry is the only sector for advanced technology, along with automotive and aerospace, where Europe plays an equal if not sometimes better than the main global competitors,” says Stefano da Empoli, president of I- com and author of the report with David Integlia and Nicola Salerno. But at this point, especially faced with the dilemma of sustainability of health systems that invests Europe as the U.S. and Japan, to consolidate the results of the health industry and together give the best services to European citizens, it is time to look at ” more and more towards the European dimension – says da Empoli – abandoning localism exasperated the past fifteen years. “
Export
Super, super production
According to the study of Europe (210 billion euro) in the pharmaceutical industry exceeds U.S. (143 billion) and Japan (68 bn) for production capacity, with a trend of increase of 22% compared to 2005. Between 2005 and 2012, investment in R & D grew by 38%, compared to 17% in Japan and 6% in the United States. A value that sees Italy grow by 22%. Positive fundamentals that apply to the production as for export and for the impact on value added. On the contrary as Italy, with a value in 2012 of just surpassed the 14 billion euro, has a value higher than the average of our EU partners.
restart possible in three steps:
Numbers primacy and potential from which to start, the report said. To make this industry leadership and a tow along a support for the maintenance of European healthcare systems. But as long as you put in the field appropriate policies. At least in two directions on the industrial level: with transparent and effective rules on testing and incentives and making homogeneous systems of remuneration of the therapeutic value of technology and access to care. And by focusing on integrative health with “multi-uniform pattern.”
And from here, says da Empoli, is expected to start in the field of health the presidency of the EU-led Italian. Because “in Italy more than anywhere else you are made to feel the negative effects the exaggerated regionalism. Is it possible to force a business that operates on every continent to deal with the alleged effectiveness of a drug in Campobasso or Perugia, obtained after validation by the European Agency of the drug based on the best possible scientific criteria? ». The question, given the importance of the “case stamina” in the hands of the courts, not by circumstance. It calls into question what should be the tasks and duties of the “local authorities”. Why is the proposed ‘regional administrations should lie, if anything, a better ability to attract manufacturing plants, thanks to contextual factors virtuous. Instead, the territories too often exert their function in the negative. Easier to get across to decisions made by others that explore new avenues and therefore more risky, “is the bitter conclusion of the President of I-Com.
© ALL RIGHTS RESERVED
Permalink
No comments:
Post a Comment